Company intelligence / Profile preview

Bariendo

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Bariendo’s flagship ESG Stomach Tightening procedure shows an average 18–20% weight loss, with durability up to 10 years, and is more cost-effective and effective than GLP-1 agonists over a five-year period, as verified in JAMA-published research. The platform is operational in multiple states, with strong outcomes demonstrated for their minimally invasive, non-surgical procedures.[6][4]

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: DeviceNon-pharmacological therapySmall molecule
Industry: Surgical Medical Devices

Partnerships

Fractyl Health (for Revita duodenal resurfacing procedure)Boston Scientific (Endura suite distributor and trademark owner)

Beyond the preview

Go deeper on Bariendo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bariendo.

Explore the full profile